ASLAN Successfully Concludes Initial Public Offering With Public Draw 29 Times Oversubscribed
Taipei, Taiwan, 24 May 2017 – ASLAN Pharmaceuticals (ASLAN; 6497.TT), a biotech company focused on the
development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has
successfully concluded an initial public offering (IPO) of common shares via public lottery.
2,602,000 shares were made available for the public draw at the offer price of NT$68.92.
The results of the public lottery are as follows:
- Number of total qualified deal: 76,377
- Lot winning rate: 3.4%
- The shares were 29.4 times oversubscribed.
ASLAN has raised a total of NT$1 billion (US$33 million) from the IPO process. Trading of shares on the Taipei Exchange (TPEx) will commence on 1 June 2017.
Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said, “The conclusion of the public lottery represents the successful closing of our initial public offering, an important milestone in ASLAN’s development. We are delighted to have attracted such strong investor support, it is a significant endorsement of our strategy, pipeline and team. We now look forward to focusing on executing our clinical development and commercialisation strategy as we prepare to initiate global pivotal studies of varlitinib.”
ASLAN has a pipeline of five novel compounds and one modybodies platform, focusing on the treatment of Asiaprevalent tumours. Its lead asset, varlitinib, has commenced a global pivotal study in biliary tract cancer following the Investigational New Drug approval from the US Food & Drug Administration. ASLAN is led by a team of highlyexperienced industry veterans with a strong track record in clinical development. The Company has been able to generate revenues through two outlicensing deals, attract international institutional investors, and forge strong partnerships with world-leading research institutions and international biopharmaceutical companies. The results of the public lottery are available on TWSE website via http://www.twse.com.tw/zh/announcement/publicForm.
Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333
E-mail: media@aslanpharma.com
Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com
2,602,000 shares were made available for the public draw at the offer price of NT$68.92.
The results of the public lottery are as follows:
- Number of total qualified deal: 76,377
- Lot winning rate: 3.4%
- The shares were 29.4 times oversubscribed.
ASLAN has raised a total of NT$1 billion (US$33 million) from the IPO process. Trading of shares on the Taipei Exchange (TPEx) will commence on 1 June 2017.
Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said, “The conclusion of the public lottery represents the successful closing of our initial public offering, an important milestone in ASLAN’s development. We are delighted to have attracted such strong investor support, it is a significant endorsement of our strategy, pipeline and team. We now look forward to focusing on executing our clinical development and commercialisation strategy as we prepare to initiate global pivotal studies of varlitinib.”
ASLAN has a pipeline of five novel compounds and one modybodies platform, focusing on the treatment of Asiaprevalent tumours. Its lead asset, varlitinib, has commenced a global pivotal study in biliary tract cancer following the Investigational New Drug approval from the US Food & Drug Administration. ASLAN is led by a team of highlyexperienced industry veterans with a strong track record in clinical development. The Company has been able to generate revenues through two outlicensing deals, attract international institutional investors, and forge strong partnerships with world-leading research institutions and international biopharmaceutical companies. The results of the public lottery are available on TWSE website via http://www.twse.com.tw/zh/announcement/publicForm.
Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333
E-mail: media@aslanpharma.com
Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitinib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer. www.aslanpharma.com